# Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria

> **NCT07559370** · PHASE2 · RECRUITING · sponsor: **Victoria Biomedical Research Institute** · enrollment: 1116 (estimated)

## Conditions studied

- Malaria (Plasmodium Falciparum)

## Interventions

- **DRUG:** Artemether/lumefantrine tablets
- **DRUG:** Artemether/Lumefantrine + Imatinib Mesylate

## Key facts

- **NCT ID:** NCT07559370
- **Lead sponsor:** Victoria Biomedical Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-20
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 1116 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07559370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07559370, "Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07559370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*